研究单位：[1]Betta Pharmaceuticals Co.,Ltd.[2]Sichuan Cancer Hospital Chengdu,China[3]West China Hospital,Sichuan University Chengdu,China[4]Chifeng Municipal Hospital Chifeng,China[5]Army Medical Center of PLA Chongqing,China[6]Chongqing University Cancer Hospital Chongqing,China[7]Fujian Cancer Hospital Fuzhou,China[8]Fuzhou Pulmonary Hospital of Fujian Fuzhou,China[9]First Affiliated Hospital Of Gannan Medical University Ganzhou,China[10]Guangdong Province Traditional Chinese Medical Hospital Guangzhou,China[11]Sun Yat-sen Memorial Hospital,Sun Yat-sen University Guangzhou,China
研究目的：
This is a multi-center,open-label,Phase I/II clinical study of MCLA-129 as monotherapy in patients with advanced solid tumors to evaluate the safety,pharmacokinetic characteristics and antitumor activity of MCLA-129.
